Status:
COMPLETED
Tack Optimized Balloon Angioplasty Below the Knee (TOBA - BTK) Study
Lead Sponsor:
Philips Clinical & Medical Affairs Global
Conditions:
Critical Limb Ischemia
Peripheral Artery Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Multi-center study to optimize below the knee (BTK) balloon angioplasty results by creating tissue apposition in peripheral arteries with Reference Vessel Diameter's (RVD) ranging from 1.5mm to 4.5mm.
Detailed Description
This first in man (FIM) study is to collect data in support of the safety and performance of the Intact Vascular Tack-It Endovascular System™ for tissue apposition to optimize balloon angioplasty. St...
Eligibility Criteria
Inclusion
- Age of subject is \>18
- Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the consent form
- Subject has critical limb ischemia (CLI)
- Subject has Rutherford Clinical Category 4-5. (hemodynamic reference)
- Reference vessel diameter below the knee (BTK) is between 1.5mm and 4.5mm (inclusive).
- De-novo target lesion(s) has stenosis \>70%.
- Must be able to perform PTA. The PTA must result in a dissection Type A - F at some location along the treatment site.
- Any vessel intervened on must have distal reconstitution above the ankle.
- Inflow Iliac, SFA and Popliteal lesions can be treated during the same procedure using standard angioplasty and/or an approved device. These inflow lesions must be treated first, prior to consideration of treatment of BTK lesions. The patient can be enrolled if the inflow lesions are treated with good angiographic results (must have \<30% residual stenosis and no evidence of embolization).
- Key
Exclusion
- The subject has a lesion on the plantar surface of the heel or over the Achilles tendon or has exposed calcaneus.
- The subject has extensive forefoot gangrene / ischemic ulcer that cannot be resolved with standard metatarsal amputation.
- Previous treatment failure of inflow arteries (Iliac, SFA and Popliteal)
- Subject with below knee bypass.
- Subject has significant stenosis or occlusion of inflow vessels tract (proximal disease) not successfully treated (\>30% residual stenosis and/or complication of the procedure) prior to BTK angioplasty and patient enrollment.
- Subject is permanently wheel-chair bound or bedridden.
- Subject has an allergy to contrast medium that cannot be pretreated.
- Episode of acute limb ischemia within the previous 30 days.
- Subject is undergoing atherectomy in the target limb or cryoplasty or stenting of BTK treatment site.
- Subject has a systemic infection with positive blood cultures/bacteremia within one week.
- Subject has undrained pus or spreading wet gangrene in the foot that is not controlled at the time of revascularization procedure.
- Subject in whom antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated.
- Myocardial infarction within 30 days prior to enrollment.
- History of stroke within 180 days prior to enrollment.
- Subject has acute or chronic renal disease (e.g., as measured by a serum creatinine of \>2.5 mg/dL or \>220 umol/L).
- Subject has a known hypersensitivity or contraindication to nitinol.
Key Trial Info
Start Date :
December 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2017
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT02235675
Start Date
December 1 2013
End Date
February 1 2017
Last Update
April 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Universitat Graz
Graz, Austria, A-8036